Takara BioSTU:TF2 72 Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus rates STU:TF2 with a GF Score™ of 72/100 and a GF Value™ of €4.49 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 145 Biotechnology companies, Takara Bio ranks worse than 689654.48% on this metric.
As of today (2026-06-28), the Forward Annual Dividend Yield of Takara Bio is 0.00%.
As of today (2026-06-28), the Trailing Annual Dividend Yield of Takara Bio is 0.00%.
STU:TF2's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.57 * Ranked among companies with meaningful Forward Dividend Yield % only.
During the past 12 months, Takara Bio's average Dividends Per Share Growth Rate was -100.00% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Takara Bio was 73.80% per year. The lowest was -19.80% per year. And the median was 26.00% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Takara Bio (STU:TF2) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
STU:TF2 vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Takara Bio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Takara Bio's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Takara Bio (STU:TF2) has a Forward Dividend Yield % of 0.00% as of Jun. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Takara Bio and its competitors. According to the industry distribution chart, Takara Bio ranks #999999 out of 145 companies in the Biotechnology industry.
Is Takara Bio's Forward Dividend Yield % too high?
Takara Bio's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Takara Bio ranks #999999 out of 145 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Takara Bio has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #999999 out of 145 companies for Forward Dividend Yield %. This places Takara Bio in the lower half of its industry. The industry median Forward Dividend Yield % is 1.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.57, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Takara Bio and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takara Bio's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (STU:TF2) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.49, compared to a current price of €6.00 — trading 33.6% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Takara Bio's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Takara Bio (STU:TF2), the current Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (STU:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €6.00 is trading 33.6% above its estimated GF Value™ of €4.49.
GuruFocus considers Takara Bio to be Significantly Overvalued.
Key valuation signals for STU:TF2:
Forward Dividend Yield %: 0.00%
GF Value™: €4.49 vs. price of €6.00 (33.6% above fair value)
No single metric tells the full story. See the STU:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
72GF Score
Get the complete analysis for STU:TF2
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:TF2 has been successfully added to your 